|Other Names||Serine/threonine-protein kinase TAO1, Kinase from chicken homolog B, hKFC-B, MARK Kinase, MARKK, Prostate-derived sterile 20-like kinase 2, PSK-2, PSK2, Prostate-derived STE20-like kinase 2, Thousand and one amino acid protein kinase 1, TAOK1, hTAOK1, TAOK1, KIAA1361, MAP3K16, MARKK|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7085c was selected from the Center region of human TAOK1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Synonyms||KIAA1361, MAP3K16, MARKK|
|Function||Serine/threonine-protein kinase involved in various processes such as p38/MAPK14 stress-activated MAPK cascade, DNA damage response and regulation of cytoskeleton stability. Phosphorylates MAP2K3, MAP2K6 and MARK2. Acts as an activator of the p38/MAPK14 stress-activated MAPK cascade by mediating phosphorylation and subsequent activation of the upstream MAP2K3 and MAP2K6 kinases. Involved in G-protein coupled receptor signaling to p38/MAPK14. In response to DNA damage, involved in the G2/M transition DNA damage checkpoint by activating the p38/MAPK14 stress-activated MAPK cascade, probably by mediating phosphorylation of MAP2K3 and MAP2K6. Acts as a regulator of cytoskeleton stability by phosphorylating 'Thr-208' of MARK2, leading to activate MARK2 kinase activity and subsequent phosphorylation and detachment of MAPT/TAU from microtubules. Also acts as a regulator of apoptosis: regulates apoptotic morphological changes, including cell contraction, membrane blebbing and apoptotic bodies formation via activation of the MAPK8/JNK cascade.|
|Tissue Location||Highly expressed in the testis, and to a lower extent also expressed in brain, placenta, colon and skeletal muscle.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
TAOK1 is an upstream activator of Mark. TAOK1 phosphorylated Mark on a threonine within its activation loop. In brain, TAOK1 also phosphorylated a fraction of Mark on a nearby serine, and this phosphorylation inhibited Mark activity. In cells, TAOK1 activity enhanced microtubule dynamics through activation of Mark and led to phosphorylation and detachment of microtubule-associated proteins from microtubules. TAOK1 also activated JNK in vitro. Overexpression of TAOK1 in a human nonsmall cell lung carcinoma cell line induced apoptotic morphologic changes, including cell contraction, membrane blebbing, and apoptotic body formation. Apoptotic stimuli increased the catalytic activity of endogenous TAOK1 and JNK, and dominant-negative JNK or JNK inhibition blocked the apoptotic morphologic responses to TAOK1. TAOK1 also stimulated cleavage and activation of ROCK1 by caspases, leading to cell contraction and membrane blebbing. TAOK1 was itself a substrate for caspase-3. TAOK1 is indeed involved in the execution phase of apoptosis.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.